openFDA
Cure8 regulatory brief
SOLU-MEDROL FDA label update (2026-07-23)
Medications
Prednisone
Corticosteroids
Steroids
Regulatory Update
Clinicians
Patients On Biologics
Inflammatory bowel disease
Why This Matters
This label is the official prescribing information for intravenous/intramuscular methylprednisolone (SOLU‑MEDROL). Corticosteroids are commonly used short‑term in IBD to treat moderate-to-severe flares when rapid systemic therapy is needed.
Who Should Pay Attention
Adults and caregivers of people with Crohn's disease or ulcerative colitis, gastroenterology clinicians, and pharmacists.
Study Snapshot
Story typeRegulatory
Evidence typeRegulatory update
Study statusHuman prescription drug
Source depthRegulatory record
What To Know
This is an FDA/openFDA DailyMed label document for SOLU‑MEDROL (methylprednisolone sodium succinate). The label lists approved indications, including use to "tide the patient over a critical period" in regional enteritis (Crohn's disease) and ulcerative colitis, and provides dosing, administration, and safety information.
The source is a regulatory drug-label record (full text).
Keep In Mind
This record is a regulatory drug‑label (DailyMed) providing indications and administration guidance. It is not new clinical trial data; use and dosing recommendations reflect approved labeling. For individual treatment decisions, consult your clinician.
Source Details
Review the original publication for the complete reporting, methods, and context.
Regulatory update
Evidence type derived from source or registry metadata.
PublicationopenFDA
PublisherU.S. Food and Drug Administration
SponsorSportpharm LLC
Study typeDrug Label Update
Indexed viaopenFDA
Source typeRegulatory record
PublishedJul 23, 2026, 12:00 AM
Content availableRegulatory record
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Prednisone FDA label update (2026-07-13)
The FDA/DailyMed label defines approved uses and official dosing guidance for prednisone, a corticosteroid commonly used to treat moderate-to-severe inflammatory conditions including ulcerative colitis and regional...
Dexamethasone FDA label update (2026-07-07)
This is the FDA DailyMed label for dexamethasone, which lists gastrointestinal uses including short-term use in ulcerative colitis and regional enteritis (Crohn's disease). Patients with IBD may be prescribed...
Effectiveness of tofacitinib as rescue therapy in biological-naive patients with steroid-refractory acute severe ulcerative colitis: a multicentric retrospective analysis.
This study suggests tofacitinib may work quickly as a rescue option for biologic‑naive patients with steroid‑refractory ASUC and that many achieved steroid‑free remission by 24 weeks — information that could matter when...